Han Na Kang

640 total citations
18 papers, 385 citations indexed

About

Han Na Kang is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Han Na Kang has authored 18 papers receiving a total of 385 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 8 papers in Molecular Biology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Han Na Kang's work include Lung Cancer Treatments and Mutations (7 papers), Lung Cancer Research Studies (3 papers) and HER2/EGFR in Cancer Research (3 papers). Han Na Kang is often cited by papers focused on Lung Cancer Treatments and Mutations (7 papers), Lung Cancer Research Studies (3 papers) and HER2/EGFR in Cancer Research (3 papers). Han Na Kang collaborates with scholars based in South Korea, United States and United Kingdom. Han Na Kang's co-authors include Sang Cheul Oh, Young A. Yoo, Byoung Chul Cho, Myoung Hee Kang, Jun Suk Kim, Jung Lim Kim, Hyun Joo Lee, Hye Ryun Kim, Mi Ran Yun and Kyoung‐Ho Pyo and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Han Na Kang

18 papers receiving 379 citations

Peers

Countries citing papers authored by Han Na Kang

Since Specialization

Citations

This map shows the geographic impact of Han Na Kang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Han Na Kang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Han Na Kang more than expected).

Fields of papers citing papers by Han Na Kang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Han Na Kang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Han Na Kang. The network helps show where Han Na Kang may publish in the future.

Co-authorship network of co-authors of Han Na Kang

This figure shows the co-authorship network connecting the top 25 collaborators of Han Na Kang. A scholar is included among the top collaborators of Han Na Kang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Han Na Kang. Han Na Kang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	Prim-O-glucosylcimifugin attenuates intestinal fibrosis by modulating TGF-β/MAPK signaling and ECM remodeling 2025 ·Life Sciences ·Han Na Kang, (unknown), Sun Joo Lee, (unknown), Seo-Young Lee, Younghoon Go, Jun Hwan Yoo, Sang‐Min Park, Yoon Jeong Choi, Youn‐Hwan Hwang	1
2	Review projecting shikonin as a therapeutic candidate in female carcinomas: a preclinical perspective 2025 ·Frontiers in Pharmacology ·(unknown), Sorabh Lakhanpal, K. Jamuna, Ajay Veer Singh, (unknown), Moon Nyeo Park, (unknown), Han Na Kang, (unknown), Mοhd Saeed, Fahad Khan, Bonglee Kim	1
3	Paeoniae radix overcomes resistance to EGFR-TKIs via aurora B pathway suppression in lung adenocarcinoma 2024 ·Life Sciences ·(unknown), Haeseung Lee, Sang‐Min Park, Han Na Kang	3
4	Sulforaphane regulates cell proliferation and induces apoptotic cell death mediated by ROS-cell cycle arrest in pancreatic cancer cells 2024 ·Frontiers in Oncology ·Yongmin Cho, Moon Nyeo Park, Min Ji Choi, Tarun Kumar Upadhyay, Han Na Kang, (unknown), (unknown), (unknown), Moonkyoo Kong, (unknown), Md. Ataur Rahman, Abdel Halim Harrath, Bonglee Kim	8
5	The Interplay between Slow-Cycling, Chemoresistant Cancer Cells and Fibroblasts Creates a Proinflammatory Niche for Tumor Progression 2020 ·Cancer Research ·Jaebeom Cho, HJ Lee, Su Jung Hwang, Hye‐Young Min, Han Na Kang, (unknown), Seung Yeob Hyun, (unknown), Ho Jin Lee, (unknown), Young‐Ah Suh, Sungyoul Hong, Young Kee Shin, Hye Ryun Kim, Ho‐Young Lee	28
6	Abstract 5199: JNJ-61186372, an EGFR-cMet bispecific antibody, in EGFR Exon 20 insertion-driven advanced non-small cell lung cancer (NSCLC) 2020 ·Cancer Research ·Jiyeon Yun, Han Na Kang, Soo-Hwan Lee, (unknown), Chae Won Park, Jae Hwan Kim, Kyoung‐Ho Pyo, (unknown), Seok‐Young Kim, Min Hee Hong, Hye Ryun Kim, Meena Thayu, Joshua C. Curtin, Roland E. Knoblauch, Matthew V. Lorenzi, Byoung Chul Cho	3
7	YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non–Small Cell Lung Cancer 2019 ·Clinical Cancer Research ·Jiyeon Yun, Min Hee Hong, Seok‐Young Kim, (unknown), Soyoung Kim, Mi Ran Yun, Han Na Kang, Kyoung‐Ho Pyo, Sung Sook Lee, Jong Sung Koh, (unknown), (unknown), (unknown), (unknown), (unknown), Hye Ryun Kim, Byoung Chul Cho	83
8	Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK ‐rearranged lung cancer 2019 ·EMBO Molecular Medicine ·Mi Ran Yun, (unknown), You Won Lee, (unknown), Chae Won Park, Jae Woo Choi, (unknown), Han Na Kang, Kyoung‐Ho Pyo, Eun Joo Shin, Hyo Sup Shim, Ross A. Soo, James Chih‐Hsin Yang, Sung Sook Lee, Hyun Chang, Min Hwan Kim, Min Hee Hong, Hye Ryun Kim, Byoung Chul Cho	46
9	Dual-targeting of EGFR and Neuropilin-1 attenuates resistance to EGFR-targeted antibody therapy in KRAS-mutant non-small cell lung cancer 2019 ·Cancer Letters ·Ye‐Jin Kim, (unknown), (unknown), Seyoung Lee, Daechan Park, Han Na Kang, Byoung Chul Cho, Yong‐Sung Kim	24
10	Abstract 4081: Efficacy of MERTK inhibitor in combination with pembrolizumab in lung cancer 2019 ·Cancer Research ·Kyoung‐Ho Pyo, (unknown), (unknown), (unknown), Han Na Kang, Jiyeon Yun, Hye Ryun Kim, Byoung Chul Cho	1
11	Profiling of protein–protein interactions via single-molecule techniques predicts the dependence of cancers on growth-factor receptors 2018 ·Nature Biomedical Engineering ·(unknown), (unknown), Han Na Kang, Hyunwoo Kim, Ahrum Min, (unknown), Ji Young Ryu, Sangwoo Park, Jinyoung Sohn, Kihyuk Shin, Mi Ran Yun, (unknown), Min Ju Shon, Cherlhyun Jeong, Junho Chung, Seung‐Hyo Lee, Seock‐Ah Im, Byoung Chul Cho, Tae‐Young Yoon	23
12	Abstract 5012: Mouse-human co-clinical trials demonstrate superior efficacy with combinational approach of BKM120 and erbitux over BKM120 monotherapy in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M-SCCHN) 2017 ·Cancer Research ·Han Na Kang, Mi Ran Yun, Kyoung‐Ho Pyo, (unknown), Jong‐Mu Sun, Sun Min Lim, Soonmyung Paik, Byoung Chul Cho, Hye Ryun Kim	1
13	ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models 2016 ·Lung Cancer ·Han Na Kang, (unknown), Mi Ran Yun, Hye Ryun Kim, Sun Min Lim, Minsoo Kim, Kwang‐Won Hong, Sung‐Moo Kim, Il Hwan Kim, Kyoung‐Ho Pyo, (unknown), (unknown), (unknown), (unknown), Byoung Chul Cho	6
14	Establishment of a Conditional Transgenic Mouse Model Recapitulating EML4-ALK –Positive Human Non–Small Cell Lung Cancer 2016 ·Journal of Thoracic Oncology ·Kyoung‐Ho Pyo, Sun Min Lim, Hye Ryun Kim, Young Hoon Sung, Mi Ran Yun, Sung‐Moo Kim, Il Hwan Kim, Han Na Kang, (unknown), Sang Gyun Kim, Chae Won Park, Hyun Chang, Hyo Sup Shim, Han‐Woong Lee, Byoung Chul Cho	20
15	Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in RET -Rearranged Lung Adenocarcinoma 2015 ·Molecular Cancer Therapeutics ·Chan Woo Kang, (unknown), Jinyoung Sohn, Sung‐Moo Kim, Kyoung‐Ho Pyo, Il Hwan Kim, Mi Ran Yun, Han Na Kang, Hye Ryun Kim, Sun Min Lim, Yong Wha Moon, Soonmyung Paik, Dae Joon Kim, Joo Hang Kim, Byoung Chul Cho	16
16	Clinical trials outcomes of combined BKM120 and cetuximab compared to BKM120 in recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M-SCCHN). 2015 ·Journal of Clinical Oncology ·Hye Ryun Kim, Han Na Kang, Mi Ran Yun, Sun Min Lim, Chang Gon Kim, Myung‐Ju Ahn, Jong‐Mu Sun, Joo-Hang Kim, Soonmyung Paik, Byoung Chul Cho	5
17	Abrogation of Gli3 expression suppresses the growth of colon cancer cells via activation of p53 2011 ·Experimental Cell Research ·Han Na Kang, Sang Cheul Oh, Jun Suk Kim, Young A. Yoo	21
18	Metastatic function of BMP-2 in gastric cancer cells: The role of PI3K/AKT, MAPK, the NF-κB pathway, and MMP-9 expression 2011 ·Experimental Cell Research ·Myoung Hee Kang, Sang Cheul Oh, Hyun Joo Lee, Han Na Kang, Jung Lim Kim, Jun Suk Kim, Young A. Yoo	95

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact